




PHARMACEUTICAL 2020

Sio Gene Therapies Inc.
Rank 268 of 358





PHARMACEUTICAL 2020

Sio Gene Therapies Inc.
Rank 268 of 358



The relative strengths and weaknesses of Sio Gene Therapies Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sio Gene Therapies Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 28% points. The greatest weakness of Sio Gene Therapies Inc. is the variable Net Income, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is -34%, being 70% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	114,584
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	43,499
Liabilities, Non-Current	22,994
Other Assets	6,844
Other Compr. Net Income	785
Other Expenses	7,663
Other Liabilities	0
Other Net Income	5,616
Other Revenues	0
Property and Equipment	1,278
Research and Development	87,552
Selling, General and Administrative Expense	39,466

Output Variable	Value in 1000 USD
Assets	122,706
Liabilities	66,493
Expenses	134,681
Revenues	0
Stockholders Equity	56,213
Net Income	-129,065
Comprehensive Net Income	-128,672
Economic Capital Ratio	-34%